Galderma announced it has received FDA approval for a new Restylane filler, Restylane Eyelight, expanding patient options for treating under-eye hollows. The hyaluronic acid filler is specifically designed to address this common concern, also known as dark shadows or circles, and is approved for adults over the age of 21.
According to a press release, it is the first and only dermal filler in the U.S. formulated with NASHA Technology. This technology was designed to closely mimic the body’s natural hyaluronic acid, creating a supportive gel texture with minimal crosslinking. Restylane Eyelight is also resistant to water absorption, making it a more stable solution for adding volume under the eyes.
Under-eye concerns, like dark circles, can make you appear older, tired and stressed. Chicago dermatologist and lead investigator in the clinical trial, Carolyn Jacob, MD, says patients are seeking sophisticated solutions. “Many of my patients seek treatment for hollows under the eyes, and traditional products like creams and concealers don’t provide the long-lasting results they desire,” she says. “Restylane Eyelight offers a safe and effective solution, enabling my patients to achieve their aesthetic undereye goals with natural-looking outcomes that can last up to 18 months.”
“Eyelight is the first filler to be specially formulated for the under eye area. It is mildly cross linked for longevity and is designed to not absorb water to reduce swelling,” says Woodbury, NY office, oculoplastic surgeon David Schlessinger, MD. “Although I have not personally tired it, this combination of features makes it seem like a promising filler for the tear trough and eyelid area.”
In the clinical study, 87 percent of patients experienced a reduction in under-eye hollowness after three months. Most patients, 92 percent, expressed satisfaction at three months, while 84 percent said they remained pleased after one year. Remarkably, 93 percent expressed interest in receiving the treatment again after 12 months.
A Safe Option
From a safety standpoint, 87 percent of patients reported they did not experience any adverse events related to the treatment. The most common side effects were swelling, redness, tenderness, pain, bruising, itching, and lumps or bumps at the injection site. Importantly, no instances of Tyndall effect, which causes blue discoloration, were reported after the treatment.
New York oculoplastic surgeon Irene Gladstein, MD says this is very exciting, as infraorbital hollowing is a widespread issue that requires long-lasting product and refined technique. “Despite the growing choices of injectable products in undereye area, it is important to remember that managing the tear trough and volume deficiency is often the last step in full facial rejuvenation protocol and requires volume correction in other parts of the face first,” she notes.
Restylane Eyelight will be available in aesthetic practices across the country in the coming months.